KGK Science Inc.

About KGK Science Inc.

KGK Science Inc. is a premium contract research organization (CRO) located on Wellington Street in the downtown area of London, Ontario. Serving the nutraceutical, cannabis, hemp, and psychedelic industries, the company provides high-quality clinical research and expert regulatory support to help brands move products into global markets. Since 1997, the organization has focused on advancing health and wellness by offering custom-designed clinical trials and claim substantiation strategies. The company offers a comprehensive suite of services including clinical, client, preclinical, and regulatory services. Their clinical offerings include Premium Clinical Trials, which can be end-to-end or specific research services, as well as innovative virtual options such as Participant Reported Outcomes Virtual Trials (PRO-VT) and Customized Virtual Trials (C-VT). Their regulatory services are led by a former FDA regulator and include pathway-to-market analysis, gap assessments, and safety dossiers for NDI notifications and GRAS conclusions. Additionally, they provide preclinical studies managed by expert toxicologists to guide product development and safety requirements. KGK Science describes itself as a research pioneer with over 27 years of experience, having guided hundreds of companies from initial product concepts to clinically proven claims. The company is led by President and CEO Najla Guthrie, with a leadership team that includes Chief Regulatory Officer Corey Hilmas, MD PhD, and Scientific Director Erin Lewis, PhD. The organization emphasizes precision, innovation, and scientific excellence, aiming to be a trusted resource for evidence-based nutrition. They also recruit participants for natural health studies, offering compensation for those who qualify to join their clinical trials.